Journal: Life sciences

Article Title: Neutrophil elastase-mediated proteolysis of the tumor suppressor p200 CUX1 promotes cell proliferation and inhibits cell differentiation in APL.

doi: 10.1016/j.lfs.2019.117229

Figure Lengend Snippet: Fig. 4. NE co-localizes and interacts with p200 CUX1. (A) Expression levels of

Article Snippet: Primary antibodies were purchased from the following sources: against human NE (no. ab131260) from Abcam (UK); against p200 CUX1 (no. 81557), P21 Waf1/Cip1 (no. 2947), P27Kip1 (no. 3686), and C/EBPα (no. 8178) from Cell Signaling Technology (CST, USA); against p110/p75 CUX1 (no. TA890108) from Origene Technologies (Origene, USA); against C/EBPβ (no. sc-137146) from Santa Cruz Biotechnology (Santa Cruz, USA).

Techniques: Expressing

Journal: Life sciences

Article Title: Neutrophil elastase-mediated proteolysis of the tumor suppressor p200 CUX1 promotes cell proliferation and inhibits cell differentiation in APL.

doi: 10.1016/j.lfs.2019.117229

Figure Lengend Snippet: Fig. 5. NE effectively hydrolyzes p200 CUX1. (A) NE overexpression decreased

Article Snippet: Primary antibodies were purchased from the following sources: against human NE (no. ab131260) from Abcam (UK); against p200 CUX1 (no. 81557), P21 Waf1/Cip1 (no. 2947), P27Kip1 (no. 3686), and C/EBPα (no. 8178) from Cell Signaling Technology (CST, USA); against p110/p75 CUX1 (no. TA890108) from Origene Technologies (Origene, USA); against C/EBPβ (no. sc-137146) from Santa Cruz Biotechnology (Santa Cruz, USA).

Techniques: Over Expression

Journal: Life sciences

Article Title: Neutrophil elastase-mediated proteolysis of the tumor suppressor p200 CUX1 promotes cell proliferation and inhibits cell differentiation in APL.

doi: 10.1016/j.lfs.2019.117229

Figure Lengend Snippet: Fig. 6. p200 CUX1 overexpression reverses the effects of NE on cell proliferation

Article Snippet: Primary antibodies were purchased from the following sources: against human NE (no. ab131260) from Abcam (UK); against p200 CUX1 (no. 81557), P21 Waf1/Cip1 (no. 2947), P27Kip1 (no. 3686), and C/EBPα (no. 8178) from Cell Signaling Technology (CST, USA); against p110/p75 CUX1 (no. TA890108) from Origene Technologies (Origene, USA); against C/EBPβ (no. sc-137146) from Santa Cruz Biotechnology (Santa Cruz, USA).

Techniques: Over Expression

Journal: bioRxiv

Article Title: Chondroitin and dermatan sulfate exposure induces a wound healing state in fibroblasts through Cux1-mediated SerpinB2 transcriptional repression

doi: 10.1101/2023.08.01.551410

Figure Lengend Snippet: (A) Enrichment of transcription factor binding sites in the promoters of the genes in CS/DS/pML vs pDF. (B) mRNA expression levels in DF vs ML with and without surfen treatment in hCUX1. Mean relative to control cells and standard deviation as error bars were plotted, n=3. (C) Western blot for Cux1 and ß-actin in DF and ML with and without surfen treatment. (D) Immunofluorescence images for Dapi and Cux1 in DF and ML with and without surfen treatment. (E) Quantification of positive cells (%) from images in D. (F) Quantification of Cathepsin L activity in DF with and without CS/DS treatment and ML with and without surfen treatment. (G) Procathepsin L docking simulation against CS. Green and blue regions in procathepsin L represent processed and mature regions, respectively. P-values were obtained using two-tailed t-test (**** represents p<0,0001, *** represents p<0,001, * represents p<0,05 and ns means no significative differences).

Article Snippet: The primary antibodies anti-Cux1 (Abnova, #H00001523-M01) and anti-Actin (SIGMA-ALDRICH, #A2066) were diluted in blocking solution (1:500).

Techniques: Binding Assay, Expressing, Control, Standard Deviation, Western Blot, Immunofluorescence, Activity Assay, Two Tailed Test

Journal: bioRxiv

Article Title: Chondroitin and dermatan sulfate exposure induces a wound healing state in fibroblasts through Cux1-mediated SerpinB2 transcriptional repression

doi: 10.1101/2023.08.01.551410

Figure Lengend Snippet: (A) Dot plot representing chIP peaks (read depth) for Cux1 in ML cells (x-axis) compared to ML cells treated with surfen (B) Distribution of Cux1 peaks in ML cells in different types of genomic regions. (C) Motif discovery in Cux1 regions from chIP-seq, including P-values from this detection (D) Position of Cux1 peaks towards TSS (from 50kb upstream to 10kb downstream). In colors, we include all peaks (blue) or peaks with associated Cux1 motif (red) or Smad2 motif (green). (E) Average fold change expression in TSA-treated ML cells compared to untreated cells in genes with Cux1 peaks present in regions near their TSS (from -60kb to +10kb). (F) Gene ontology enrichment of genes with Cux1 peaks near their TSS and significative upregulated response after TSA treatment (G) Quantification of Acetyl H4 levels in ML cells with and without surfen treatment from chIP in hFGFR4 and hSERPINB2. (H) mRNA expression levels in ML cells with different Histone Deacetylase (HDAC) inhibitors treatments; hFGFR4 (left) and hSERPINB2 (right). Mean expression is relative to untreated cells and standard deviation as error bars were plotted, n=3. (C) reChIP with either Cux1 and GADPH or Cux1 and Smad2/3 antibodies in the FGFR4 region, using input and igG as controls. P-values were obtained using two-tailed t-test (*** represents p<0,001, ** represents p<0,01, * represents p<0,05 and ns means no significative differences).

Article Snippet: The primary antibodies anti-Cux1 (Abnova, #H00001523-M01) and anti-Actin (SIGMA-ALDRICH, #A2066) were diluted in blocking solution (1:500).

Techniques: ChIP-sequencing, Expressing, Histone Deacetylase Assay, Standard Deviation, Two Tailed Test